Haitao Yu

Dr. Haitao Yu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2016 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
HYHaitao Yu
Haitao Yu
JZJuan Zhen
Juan Zhen
YYYang Yang
Yang Yang
JGJinning Gu
Jinning Gu
SWSuisheng Wu
Suisheng Wu
QLQuan Liu
Quan Liu
Ginsenoside Rg1 has been demonstrated to have cardiovascular protective effects. However, whether the cardioprotective effects of ginsenoside Rg1 are mediated by endoplasmic reticulum (ER) stress‐induced apoptosis remain unclear. In this study, among 80 male Wistar rats, 15 rats were randomly selected as controls; the remaining 65 rats received a diet rich in fat and sugar content for 4 weeks, followed by intraperitoneal injection of streptozotocin (STZ, 40 mg/kg) to establish a diabetes model. Seven days after STZ injection, 10 rats were randomly selected as diabetic model (DM) controls, 45 eligible diabetic rats were randomized to three treatment groups and administered ginsenoside Rg1 in a dosage of 10, 15 or 20 mg/kg/day, respectively. After 12 weeks of treatment, rats were killed and serum samples obtained to determine cardiac troponin (cTn)‐I. Myocardial tissues were harvested for morphological analysis to detect myocardial cell apoptosis, and to analyse protein expression of glucose‐regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), and Caspase‐12. Treatment with ginsenoside Rg1 (10–20 mg/kg) significantly reduced serum cTnI levels compared with DM control group (all P < 0.01). Ginsenoside Rg1 (15 and 20 mg/kg) significantly reduced the percentage of apoptotic myocardial cells and improved the parameters of cardiac function. Haematoxylin and eosin and Masson staining indicated that ginsenoside Rg1 could attenuate myocardial lesions and myocardial collagen volume fraction. Additionally, ginsenoside Rg1 significantly reduced GRP78, CHOP, and cleaved Caspase‐12 protein expression in a dose‐dependent manner. These findings suggest that ginsenoside Rg1 appeared to ameliorate diabetic cardiomyopathy by inhibiting ER stress‐induced apoptosis in diabetic rats.

12 May 2015 in Journal of Zhejiang University-SCIENCE B
Verified
Journal Article
Open access
PDF file
HYHaitao Yu
Haitao Yu
JZJuan Zhen
Juan Zhen
BPBo Pang
Bo Pang
JGJin-Ning Gu
Jin-Ning Gu
SWSui-Sheng Wu
Sui-Sheng Wu
We evaluated the cardioprotective effects of ginsenoside Rg1 in a diabetic rat model induced with high-fat diet and intraperitoneal injection of streptozotocin. Ginsenoside Rg1 was injected intraperitoneally for 12 weeks. Myocardial injury indices and oxidative stress markers were determined. Changes in cardiac ultrastructure were evaluated with transmission electron microscopy. Myocardial apoptosis was assessed via terminal deoxynucleotidyl transferase (TDT)-mediated DNA nick-end labeling (TUNEL) and immunohistochemistry. Ginsenoside Rg1 was associated with a significant dose-dependent reduction in serum levels of creatinine kinase MB and cardiac troponin I, and lessened ultrastructural disorders in diabetic myocardium, relative to the untreated diabetic model rats. Also, compared with the untreated diabetic rats, significant reductions in serum and myocardial levels of malondialdehyde were noted in the ginsenoside Rg1-treated groups, and increased levels of the antioxidants (superoxide dismutase, catalase, and glutathione peroxidase) were detected. TUNEL staining indicated reduced myocardial apoptosis in ginsenoside Rg1-treated rats, which may be associated with reduced levels of caspase-3 (CASP3) and increased levels of B-cell lymphoma-extra-large (Bcl-xL) in the diabetic myocardium. Ginsenoside Rg1 treatment of diabetic rats was associated with reduced oxidative stress and attenuated myocardial apoptosis, suggesting that ginsenoside Rg1 may be of potential preventative and therapeutic value for cardiovascular injury in diabetic patients. 探讨人参皂苷Rg1 对高血糖所致心肌损害的保护作用及其机制。 使用糖尿病大鼠为实验对象, 探讨三种浓度的人参皂苷Rg1对糖尿病心肌损伤的保护作用及其机制, 检测其是否具有浓度依赖性。 将60 只Wistar 大鼠随机分组, 其中空白对照组10 只, 另50 只给予高脂高糖饲养, 4 周后腹腔注射40 mg/kg 链脲佐菌素 (STZ) 。成功制备糖尿病大鼠模型40 只, 再随机分为糖尿病模型组, 糖尿病大鼠+低剂量人参皂苷Rg1 (10 mg/(kg·d)), 糖尿病大鼠+中剂量人参皂苷Rg1 (15 mg/(kg·d)), 糖尿病大鼠+高剂量人参皂苷Rg1 (20 mg/(kg·d))。12 周后处死大鼠, 取血测定空腹血糖、总胆固醇 (TC)、甘油三酯 (TG)、心肌酶及氧化应激水平, 留取心肌组织使用透射电镜观察心肌细胞超微结构改变, 应用TUNEL 法检测心肌细胞凋亡, 免疫组化检测细胞凋亡相关蛋白半胱氨酸天冬氨酸蛋白酶3 (CASP3) 和Bcl-xL 的表达。 人参皂苷Rg1对糖尿病大鼠糖脂代谢无明显影响, 人参皂苷Rg1 可降低糖尿病大鼠血清肌钙蛋白 (cTnI) 和肌酸激酶同工酶 (CK-MB) 水平, 改善心肌细胞超微结构, 减少心肌细胞凋亡, 降低大鼠血清和心肌组织中丙二醛 (MDA) 含量, 提高超氧化物歧化酶 (SOD)、过氧化氢酶 (CAT) 和谷胱甘肽过氧化物酶 (GSH) 水平, 降低凋亡蛋白CASP3 的表达, 同时提高Bcl-xL 蛋白表达。总之, 人参皂苷Rg1 能显著保护糖尿病大鼠心肌损伤, 其机制可能与其抗氧化及抗细胞凋亡作用有关。

10 June 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JZJuan Zhen
Juan Zhen
XSXia Sheng
Xia Sheng
TCTianlong Chen
Tianlong Chen
HYHaitao Yu
Haitao Yu
Diabetic cardiomyopathy (DCM) is a prevalent myocardial microvascular complication of the myocardium with a complex pathogenesis. Investigating the pathogenesis of DCM can significantly contribute to enhancing its prevention and treatment strategies. Our study revealed an upregulation of lysine acetyltransferase 2 A (Kat2a) expression in DCM, accompanied by a decrease in N6-methyladenosine (m6A) modified Kat2a mRNA levels. Our study revealed an upregulation of lysine acetyltransferase 2 A (Kat2a) expression in DCM, accompanied by a decrease in N6-methyladenosine (m6A) modified Kat2a mRNA levels. Functionally, inhibition of Kat2a effectively ameliorated high glucose-induced cardiomyocyte injury both in vitro and in vivo by suppressing ferroptosis. Mechanistically, Demethylase alkB homolog 5 (Alkbh5) was found to reduce m6A methylation levels on Kat2a mRNA, leading to its upregulation. YTH domain family 2 (Ythdf2) played a crucial role as an m6A reader protein mediating the degradation of Kat2a mRNA. Furthermore, Kat2a promoted ferroptosis by increasing Tfrc and Hmox1 expression via enhancing the enrichment of H3K27ac and H3K9ac on their promoter regions. In conclusion, our findings unveil a novel role for the Kat2a-ferroptosis axis in DCM pathogenesis, providing valuable insights for potential clinical interventions.

22 September 2023 in Phytotherapy Research
Verified
Journal Article
Closed access
JZJuan Zhen
Juan Zhen
JBJinping Bai
Jinping Bai
JLJia Liu
Jia Liu
HMHongbo Men
Hongbo Men
HYHaitao Yu
Haitao Yu

25 November 2019 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
HYHaitao Yu
Haitao Yu
JZJuan Zhen
Juan Zhen
JXJian-Xiang Xu
Jian-Xiang Xu
LCLu Cai
Lu Cai
JLJi-Yan Leng
Ji-Yan Leng
Bradley B. KellerBradley B. Keller
Bradley B. Keller

16 June 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
HYHaitao Yu
Haitao Yu
JZJuan Zhen
Juan Zhen
YYYang Yang
Yang Yang
JDJian Du
Jian Du
JLJiyan Leng
Jiyan Leng
QTQian Tong
Qian Tong
Our previous studies have assessed ginsenoside Rg1 (Rg1)‐mediated protection in a type 1 diabetes rat model. To uncover the mechanism through which Rg1 protects against cardiac injury induced by diabetes, we mimicked diabetic conditions by culturing H9C2 cells in high glucose/palmitate. Rg1 had no toxic effect, and it alleviated the high glucose/palmitate damage in a dose‐dependent manner, as indicated by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide assay and lactate dehydrogenase release to the culture medium. Rg1 prevented high glucose/palmitate‐induced cell apoptosis, assessed using cleaved caspase‐3 and terminal deoxynucleotidyl transferase dUTP nick end labelling staining. Rg1 also reduced high glucose‐/palmitate‐induced reactive oxygen species formation and increased intracellular antioxidant enzyme activity. We found that Rg1 activates protein kinase B (AKT)/glycogen synthase kinase‐3 (GSK‐3β) pathway and antioxidant nuclear factor erythroid 2‐related factor 2 (Nrf2) pathway, indicated by increased phosphorylation of AKT and GSK‐3β, and nuclear translocation of Nrf2. We used phosphatidylinositol‐3‐kinase inhibitor Ly294002 to block the activation of the AKT/GSK‐3β pathway and found that it partially reversed the protection by Rg1 and decreased Nrf2 pathway activation. The results suggest that Rg1 exerts a protective effect against high glucose and palmitate damage that is partially AKT/GSK‐3β/Nrf2‐mediated. Further studies are required to validate these findings using primary cardiomyocytes and animal models of diabetes.